Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Continuing with its business model of launching therapeutically focused biotechs around in-licensed mid- or late-stage assets, Roivant Sciences GMBH licensed Ligand Pharmaceuticals Inc.'s Phase II glucagon receptor antagonist (GRA) for type 2 diabetes on March 6
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?